ACADIA Pharmaceuticals Inc. (ACAD) Financial Statements (2024 and earlier)

Company Profile

Business Address 12830 EL CAMINO REAL
SAN DIEGO, CA 92130
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2023
MRQ
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments416,823520,706631,958697,429473,520341,342
Cash and cash equivalents114,846147,435326,028189,680134,75869,418
Short-term investments301,977373,271305,930507,749338,762271,924
Receivables63,08065,34450,28237,87427,78918,430
Inventory, net of allowances, customer advances and progress billings11,56014,0989,6826,3414,0705,248
Inventory11,56014,0989,6826,3414,0705,248
Prepaid expense21,39823,89225,69418,60620,7278,457
Other undisclosed current assets(4,924)(6,217)    
Total current assets:507,937617,823717,616760,250526,106373,477
Noncurrent Assets
Operating lease, right-of-use asset55,57358,26847,2839,524
Property, plant and equipment6,0218,0479,1613,1803,3092,662
Intangible assets, net (including goodwill)  1,1082,5854,0625,538
Intangible assets, net (excluding goodwill)  1,1082,5854,0625,538
Restricted cash and investments5,7705,7705,7704,7874,826 
Other noncurrent assets7,5873,9971,6782,8571,899354
Other undisclosed noncurrent assets4,9246,217   2,475
Total noncurrent assets:79,87582,29965,00022,93314,09611,029
TOTAL ASSETS:587,812700,122782,616783,183540,202384,506
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities125,63096,068105,96774,82659,56549,030
Accounts payable12,7466,8768,4937,2223,1678,786
Accrued liabilities112,88489,19297,47467,60456,39840,244
Total current liabilities:125,63096,068105,96774,82659,56549,030
Noncurrent Liabilities
Long-term debt and lease obligation:  56,12644,4606,361  
Liabilities, other than long-term debt61,7697,0345,1802,861  
Other liabilities9,0747,0345,1802,861  
Operating lease, liability52,69556,12644,4606,361
Other undisclosed noncurrent liabilities     1,558191
Total noncurrent liabilities:61,76963,16049,6409,2221,558191
Total liabilities:187,399159,228155,60784,04861,12349,221
Equity
Equity, attributable to parent400,413540,894627,009699,135479,079335,285
Common stock161616151412
Additional paid in capital2,770,9232,694,6462,612,6632,402,9451,948,3001,559,343
Accumulated other comprehensive income (loss)(975)(192)36297(372)(399)
Accumulated deficit(2,369,551)(2,153,576)(1,985,706)(1,704,122)(1,468,863)(1,223,671)
Total equity:400,413540,894627,009699,135479,079335,285
TOTAL LIABILITIES AND EQUITY:587,812700,122782,616783,183540,202384,506

Income Statement (P&L) ($ in thousands)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Revenues517,235484,145441,755339,076223,807124,901
Revenue, net124,901
Cost of revenue(10,166)(19,141)(20,550)(19,598)(18,330)(13,760)
Cost of goods and services sold(10,166)(10,843)(10,211)(11,344)(2,700)(13,760)
Other undisclosed gross profit(1)8,29810,3398,2545,9534,683
Gross profit:507,068473,302431,544327,732211,430115,824
Operating expenses(730,665)(635,443)(707,791)(566,023)(452,921)(404,251)
Other undisclosed operating income (loss)1(8,298)(10,339)(8,254)(5,953)(3,983)
Operating loss:(223,596)(170,439)(286,586)(246,545)(247,444)(292,410)
Nonoperating income (expense)3,542(2,329)(1,994)1,994(3,680) 
Investment income, nonoperating   (997)997(1,840) 
Other nonoperating income (expense)3,542(2,329)(997)997(1,840) 
Other undisclosed income from continuing operations before equity method investments, income taxes   7,60710,1687,1884,126
Loss from continuing operations before equity method investments, income taxes:(220,054)(172,768)(280,973)(234,383)(243,936)(288,284)
Other undisclosed income from continuing operations before income taxes6,6105,249    
Loss from continuing operations before income taxes:(213,444)(167,519)(280,973)(234,383)(243,936)(288,284)
Income tax expense(2,531)(351)(611)(876)(1,256)(1,119)
Loss from continuing operations:(215,975)(167,870)(281,584)(235,259)(245,192)(289,403)
Loss before gain (loss) on sale of properties:(167,870)(281,584)(235,259)(245,192)(289,403)
Net loss available to common stockholders, diluted:(215,975)(167,870)(281,584)(235,259)(245,192)(289,403)

Comprehensive Income ($ in thousands)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Net loss:(215,975)(167,870)(281,584)(235,259)(245,192)(289,403)
Other comprehensive income (loss) (783)(228)(261)66927(505)
Other undisclosed comprehensive loss      
Comprehensive loss:(216,758)(168,098)(281,845)(234,590)(245,165)(289,908)
Other undisclosed comprehensive income, net of tax, attributable to parent      
Comprehensive loss, net of tax, attributable to parent:(216,758)(168,098)(281,845)(234,590)(245,165)(289,908)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: